H. R. Hygiene Products Share Price & Earnings Call Analysis
- Market cap
- ₹141 Cr
- P/E
- 12.33
- ROE
- 30.91%
- PEG
- 0.05
- Price to sales
- 1.08
- Debt to equity
- 0.51
- EBITDA margin
- 13.58%
- Net profit margin
- 8.75%
- Promoter holding
- 48.54%
- Sales (last year)
- ₹130 Cr
Potential multibaggers · Q2 FY27
Potential multibaggers in Personal Products
on management's own guidance
- Strong growth2
- Strong growth1
- Honasa Consumer LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Personal Products companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹1,858 Cr | 55.5 | |
| 2 | 40%+ | Flat | ₹408 Cr | 36.4 | |
| 3 | Honasa Consumer Ltd | 20–40% | Up 0–2% | ₹14,422 Cr | 57.1 |
| 4 | 10–20% | Flat | ₹83,720 Cr | 39.4 | |
| 5 | 10–20% | Flat | ₹64,856 Cr | 32.7 | |
| 6 | 10–20% | Flat | ₹15,704 Cr | 20.7 |
Sign up free to see every company in the sector ranking and track H. R. Hygiene.
Pro shows every company guiding 40%+ revenue growth →Full Personal Products rankingFinancials of H. R. Hygiene
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
H. R. Hygiene
Shareholding breakup across reporting periods.
| Aug 2026 | |
|---|---|
| Promoters + | 48.54% |
| FIIs + | 8.25% |
| DIIs + | 3.55% |
| Public + | 39.64% |
| No. of Shareholders | 921 |
Financials of H. R. Hygiene
Quarterly Results
Quarter-by-quarter operating performance
| Sales + |
| Expenses + |
| Operating Profit |
| OPM % |
| Other Income + |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| Net Profit + |
| EPS in Rs |
Financials of H. R. Hygiene
Profit & Loss
Annual income statement trend
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales + | 42 | 82 | 115 | 130 |
| Expenses + | 40 | 75 | 100 | 113 |
| Operating Profit | 2 | 6 | 15 | 18 |
| OPM % | 5.0% | 8% | 13% | 14% |
| Other Income + | 0 | 2 | 1 | 1 |
| Interest | 1 | 2 | 2 | 2 |
| Depreciation | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 7 | 12 | 16 |
| Tax % | -4% | 26% | 25% | 28% |
| Net Profit + | 0 | 5 | 9 | 11 |
| EPS in Rs | 1.54 | 27.77 | 12.75 | 6.41 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
Financials of H. R. Hygiene
Balance Sheet
Capital structure and asset base
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 2 | 2 | 7 | 18 |
| Reserves | -0 | 5 | 24 | 25 |
| Borrowings + | 20 | 25 | 21 | 22 |
| Other Liabilities + | 13 | 18 | 38 | 107 |
| Total Liabilities | 34 | 49 | 91 | 171 |
| Fixed Assets + | 3 | 8 | 7 | 6 |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| Other Assets + | 31 | 41 | 83 | 165 |
| Total Assets | 34 | 49 | 91 | 171 |
Financials of H. R. Hygiene
Cash Flows
Operating, investing and financing cash movement
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from Operating Activity + | -1 | 2 | -10 | 2 |
| Cash from Investing Activity + | -0 | -6 | -0 | -0 |
| Cash from Financing Activity + | 2 | 4 | 11 | -1 |
| Net Cash Flow | 0 | -0 | 1 | 0 |
| Free Cash Flow | -2 | -4 | -10 | 1 |
| CFO/OP | -63% | 48% | -58% | 9% |
Financials of H. R. Hygiene
Ratios
Working capital efficiency and return ratios
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 40 | 28 | 157 | 293 |
| Inventory Days | 181 | 185 | 108 | 171 |
| Days Payable | 132 | 83 | 138 | 354 |
| Cash Conversion Cycle | 88 | 130 | 127 | 110 |
| Working Capital Days | 71 | 49 | 106 | 130 |
| ROCE % | 31% | 34% | 30% |
Continue your research
Others in Personal Products this season
- JHS Svendgaard Laboratories (Q2 FY27)
2,077.1 lakhs in the same quarter of 2025, which reflects an approximate year-on-year growth of 10.8%. Key results statement takeaways from JHS Svendgaard Labor
- Aakaar Medical (Q2 FY27)
Revenue from operations in H1 FY27: INR 43.72 Cr, up 72.6% YoY from INR 25.32 Cr in H1 FY26 (Page 12, 11, 4) . Key investor presentation takeaways from Aakaar M
- Recode Studios (Q4 FY26)
The company plans to sustain marketing spends at about 20% of revenue to support growth and brand visibility, implying continued focus on operating profits…
- Godrej Consumer (Q2 FY27)
Consolidated net sales for Q2 FY2027: ₹4,396 crore, up 19% year-on-year; constant currency growth 15% (Page 8) . Key investor presentation takeaways from Godrej
